The degree of bone mineralization is maintained with single intravenous bisphosphonates in aged estrogen-deficient rats and is a strong predictor of bone strength
The degree of bone mineralization is maintained with single intravenous bisphosphonates in aged estrogen-deficient rats and is a strong predictor of bone strength
复制标题
DOI：
10.1016/j.bone.2007.06.021
复制
发表时间：
2007-11-01
期刊：
影响因子：
4.1
通讯作者：
Lane, Nancy E.
中科院分区：
文献类型：
--
作者：
Yao, Wei;Cheng, Zhiqiang;Lane, Nancy E.
用双膦酸盐治疗骨质疏松症妇女可显著降低骨折发生率，其程度大于骨矿物质密度的增加。在这项研究中，18个月大的Fischer 344大鼠卵巢切除，并给予单剂量利塞膦酸（静脉，静脉，500 μ g），唑来膦酸（静脉，100 μ g）或连续雷洛昔芬（2 mg/kg, po， 3次/周）治疗。采用高分辨率显微ct测量腰椎骨微结构、骨矿化程度（DBM）及矿物分布。采用小角x射线散射法研究矿物结晶度。我们发现雌激素长期缺乏，小梁骨体积减少，微结构骨压缩强度增加，矿化程度降低。用吸收剂（双膦酸盐和雷洛昔芬）治疗可防止矿化、骨小梁体积和骨压缩强度的损失。OVX或抗吸收治疗均未改变晶体大小。综上所述，在老年雌激素缺乏大鼠模型中，单次静脉注射两种双膦酸盐可通过减少骨转换来有效维持骨抗压强度180天，并且比雷洛昔芬更能维持DBM。(c) 2007爱思唯尔公司版权所有。
The treatment of osteoporotic women with bisphosphonates significantly reduces the incidence of bone fractures to a degree greater than can be explained by an increase in bone mineral density. In this study, 18 month Fischer 344 rats were ovariectornized and treated with a single dose of risedronate (intravenous, iv, 500 mu g), zoledronic acid (iv, 100 mu g) or continuous raloxifene (2 mg/kg, po, 3x/week). High resolution microCT was used to measure lumbar vertebral bone microarchitecture, the degree of bone mineralization (DBM) and the distribution of mineral. Small angle Xray scattering was used to investigate mineral crystallinity. We found prolonged estrogen deficiency, reduced trabecular bone volume, and increased micro architecture bone compression strength lowered the degree of mineralization. Treatment with resorptive agents (bisphosphonates > raloxifene) prevented the loss of mineralization, trabecular bone volume and bone compression strength. Crystal size was not changed with OVX or with anti-resorptive treatments. In conclusion, in the aged estrogen-deficient rat model, single intravenous doses of two bisphosphonates were effective in maintaining the compressive bone strength for 180 days by reducing bone turnover, and maintaining the DBM to a greater degree than with raloxifene. (c) 2007 Elsevier Inc. All rights reserved.